3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fulvestrant
127
Trastuzumab
117
Paclitaxel
113
Letrozole
109
pembrolizumab
81
palbociclib
76
pertuzumab
75
Capecitabine
75
Anastrozole
72
Cyclophosphamide
70
Carboplatin
67
abemaciclib
65
exemestane
63
Tamoxifen
63
ribociclib
61
trastuzumab deruxtecan
58
Surveys and Questionnaires
51
Specimen Handling
51
Radiotherapy
50
Docetaxel
49
Magnetic Resonance Spectroscopy
48
Blood Specimen Collection
42
olaparib
40
Standard of Care
36
Biopsy
33
sacituzumab govitecan
32
130-nm albumin-bound paclitaxel
32
Exercise
30
Doxorubicin
30
eribulin
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Interleukin-15
×
1 year
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled